NCT03197714 - Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 7, 2017

Primary Completion Date

March 31, 2020

Study Completion Date

March 31, 2020

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

OPB-111077

"Two dose schemas will be employed:~* Level 1: 200 mg daily~* Level 2: 250 mg daily"

Trial Locations (6)

Hospital San Pedro Alcántara, Cáceres

MD Anderson Cancer Center, Madrid

Hospital 12 Octubre, Madrid

Hospital Universitario Madrid Sanchinarro, Madrid

Hospital Virgen del Rocío, Seville

Hospital Universitario La Fe, Valencia